EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy

Brian Warnecke, Misako Nagasaka iD

Drug Design, Development and Therapy · 2024-12 · Volume 18 · 5673-5683

DOI: 10.2147/dddt.s466217 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024-12. Verfasst von Brian Warnecke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansPyrimidinesDrug DesignMutationDrug DevelopmentAnimalsAcetonitrilesPiperazines

Stichwörter der Autor:innen

AMG510CodeBreaKKRYSTALKristen Rat Sarcoma Viral Oncogene HomologMRTX849brain penetrationsotorasib

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic AgentsadagrasibPyrimidinesAcetonitrilesPiperazines

Autor:innen und Institutionen

  • Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA.
  • Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

ORCID-Profile: Misako Nagasaka

Zitieren

APA

Warnecke, B., & Nagasaka, M. (2024). Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Drug Design, Development and Therapy, Volume 18, 5673-5683. https://doi.org/10.2147/dddt.s466217

Vancouver

Warnecke B, Nagasaka M. Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Drug Design, Development and Therapy. 2024;Volume 18:5673-5683. doi:10.2147/dddt.s466217

BibTeX
@article{Warnecke2024,
  author = {Warnecke, Brian and Nagasaka, Misako},
  title = {Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {5673--5683},
  doi = {10.2147/dddt.s466217}
}
Kostenlos starten →